Synthetic lethality by targeting the RUVBL1/2-TTT complex in mTORC1-hyperactive cancer cells
-
- Seung Ho Shin
- The Hormel Institute, University of Minnesota, Austin, MN 55912, USA.
-
- Ji Su Lee
- Division of Bioengineering, Incheon National University, Incheon 22012, Republic of Korea.
-
- Jia-Min Zhang
- Massachusetts General Hospital Cancer Center, Building 149 13th Street, Charlestown, MA 02129, USA.
-
- Sungbin Choi
- Division of Bioengineering, Incheon National University, Incheon 22012, Republic of Korea.
-
- Zarko V. Boskovic
- Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
-
- Ran Zhao
- School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China.
-
- Mengqiu Song
- School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China.
-
- Rui Wang
- School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China.
-
- Jie Tian
- School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China.
-
- Mee-Hyun Lee
- School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China.
-
- Jae Hwan Kim
- Department of Agricultural Biotechnology, Seoul National University, Seoul 08826, Korea.
-
- Minju Jeong
- Department of Agricultural Biotechnology, Seoul National University, Seoul 08826, Korea.
-
- Jung Hyun Lee
- Division of Dermatology, Department of Medicine, University of Washington, Seattle, WA 98109, USA.
-
- Michael Petukhov
- Petersburg Nuclear Physics Institute named after B.P. Konstantinov, NRC "Kurchatov Institute", Gatchina, Russia.
-
- Sam W. Lee
- Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA.
-
- Sang Gyun Kim
- Department of Cell Biology, Harvard Medical School, 240 Longwood Ave, Boston, MA 02115, USA.
-
- Lee Zou
- Massachusetts General Hospital Cancer Center, Building 149 13th Street, Charlestown, MA 02129, USA.
-
- Sanguine Byun
- Division of Bioengineering, Incheon National University, Incheon 22012, Republic of Korea.
抄録
<jats:p>Cancer cells with high mTORC1 activity rely on the RUVBL1/2-TTT pathway for survival, thereby providing a therapeutic window.</jats:p>
収録刊行物
-
- Science Advances
-
Science Advances 6 (31), 1-, 2020-07-31
American Association for the Advancement of Science (AAAS)